NPPA Committee Asks Intas to Clarify Patent Discrepancy in Clozapine ER Pricing Plea
New Delhi: The Multidisciplinary Committee (MDC) of Experts under the National Pharmaceutical Pricing Authority (NPPA) has asked Intas Pharmaceuticals Pvt. Ltd. to furnish clarifications over alleged inconsistencies in the patent details submitted for Clozapine Extended Release (ER) 12.5 mg/25 mg/50 mg/100 mg/200 mg capsules.
The company had applied for exemption under Paragraph 32 (ii & iii) of the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The application was first reviewed during the 64th MDC meeting held on December 6, 2024, but was deferred pending further examination and input from the Department for Promotion of Industry and Internal Trade (DPIIT).
At the 66th MDC meeting on March 3, 2025, a representative of DPIIT informed the committee that the application forwarded by NPPA was “at an advanced stage of examination.” The committee then “requested that the comments may be shared with NPPA by 15th March 2025 so that the matter may be deliberated in [the] next meeting for early disposal.”
However, during the 67th MDC meeting on April 2, 2025, no representative from DPIIT was present, and no comments were submitted. The committee again deferred the agenda and directed to pursue the matter with DPIIT for early inputs.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.